Imedconsent LLC D/B/A Dialog Medical is categorized under Health Services in Duluth, GA and active since 2010.
Imedconsent LLC D/B/A Dialog Medical was established in 2010, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Health Services business, which does work in the B2C market, and is classified as a Health Services, under code number 621999 by the NAICS.
If you are seeking more information, feel free to contact Jo Lynn Pierce at the company’s single location by writing to 3075 Breckinridge Boulevard # 425, Duluth, Georgia GA 30096 or by phoning (770) 982-7851. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Imedconsent LLC D/B/A Dialog Medical |
Contact Person: | Jo Lynn Pierce |
Address: | 3075 Breckinridge Boulevard # 425, Duluth, Georgia 30096 |
Phone Number: | (770) 982-7851 |
Annual Revenue (USD): | $100.000 to $499.999 |
Founded: | 2010 |
Location Type: | Single Location |
Employee Number: | 1 to 4 |
Business Type: | B2C (Business to Consumer) |
Business Category: | Health Services |
SIC Code: | 8099 |
NAICS Code: | 621999 |
Share This Business: |
Imedconsent LLC D/B/A Dialog Medical was started in 2010 to provide professional Health Services under the SIC code 8099 and NAICS code 621999. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Jo Lynn Pierce for inquiries that concern Imedconsent LLC D/B/A Dialog Medical by calling the company number (770) 982-7851, as your correspondence is most welcome. Additionally, the physical location of the single location of Imedconsent LLC D/B/A Dialog Medical can be found at the coordinates 33.958535,-84.110507 as well as the street address 3075 Breckinridge Boulevard # 425 in Duluth, Georgia 30096.
For its online presence, you may visit Imedconsent LLC D/B/A Dialog Medical’s website at and engage with its social media outlets through on Twitter and on Facebook.